Genentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients.
The MM+M Podcast 10.29.2020: Genentech’s Quita Highsmith
Quita Highsmith speaks about the biotech’s efforts to recruit and instill more trust among underserved and medically disenfranchised patients.